Elan courts shareholders with long-term Tysabri dividend
This article was originally published in Scrip
Executive Summary
Elan has thrown another sop to shareholders, apparently aimed at keeping them sweet while it works out its future investment plans and attempts to ward off a takeover bid. It has promised to pay a regular dividend linked to the future royalties it will receive from Biogen Idec on sales of Tysabri (natalizumab), the blockbuster multiple sclerosis drug.